## Suraj B Sable

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1648347/publications.pdf Version: 2024-02-01



SIIDAL R SARLE

#	Article	IF	CITATIONS
1	Nanobead-based interventions for the treatment and prevention of tuberculosis. Nature Reviews Microbiology, 2010, 8, 827-834.	28.6	127
2	Bacillus Calmette-Guérin vaccination using a microneedle patch. Vaccine, 2011, 29, 2626-2636.	3.8	85
3	Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clinical Microbiology Reviews, 2019, 33, .	13.6	70
4	An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection. Immunology and Cell Biology, 2007, 85, 160-168.	2.3	57
5	Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunology and Medical Microbiology, 2005, 45, 87-93.	2.7	48
6	Mycobacterium tuberculosis components stimulate production of the antimicrobial peptide hepcidin. Tuberculosis, 2011, 91, 314-321.	1.9	48
7	Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine, 2005, 23, 4175-4184.	3.8	38
8	Tuberculosis subunit vaccine design: The conflict of antigenicity and immunogenicity. Clinical Immunology, 2007, 122, 239-251.	3.2	37
9	Attrition of T-Cell Functions and Simultaneous Upregulation of Inhibitory Markers Correspond with the Waning of BCG-Induced Protection against Tuberculosis in Mice. PLoS ONE, 2014, 9, e113951.	2.5	36
10	Peripheral Blood and Pleural Fluid Mononuclear Cell Responses to Low-Molecular-Mass Secretory Polypeptides of <i>Mycobacterium tuberculosis</i> in Human Models of Immunity to Tuberculosis. Infection and Immunity, 2005, 73, 3547-3558.	2.2	32
11	O-mannosylation of the Mycobacterium tuberculosis Adhesin Apa Is Crucial for T Cell Antigenicity during Infection but Is Expendable for Protection. PLoS Pathogens, 2013, 9, e1003705.	4.7	30
12	Cellular Immune Responses to Nine Mycobacterium tuberculosis Vaccine Candidates following Intranasal Vaccination. PLoS ONE, 2011, 6, e22718.	2.5	28
13	Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. Clinical Immunology, 2007, 125, 173-183.	3.2	26
14	Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. European Respiratory Journal, 2006, 29, 337-346.	6.7	20
15	Human immune recognition-based multicomponent subunit vaccines against tuberculosis. European Respiratory Journal, 2005, 25, 902-910.	6.7	19
16	Tuberculosis subunit vaccine development: Impact of physicochemical properties of mycobacterial test antigens. Vaccine, 2007, 25, 1553-1566.	3.8	18
17	Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis. Scientific Reports, 2016, 6, 25837.	3.3	16
18	Immunodominance of low molecular weight secretory polypeptides of Mycobacterium tuberculosis to induce cytotoxic T-lymphocyte response. Vaccine, 2005, 23, 4947-4954.	3.8	9

#	Article	IF	CITATIONS
19	Programmed Death 1 Lives Up to Its Reputation in Active Tuberculosis. Journal of Infectious Diseases, 2013, 208, 541-543.	4.0	8
20	Role of Hepcidin in the Innate Immune Response to <i>Mycobacterium tuberculosis</i> . FASEB Journal, 2008, 22, 556-556.	0.5	2